With CKD stage 2 as cut off, CKD-EPI yields a prevalence of 9.6% (35 cases; not visible in the table), and cystatin C a prevalence of 27.8% (101 cases), with around 20% of the persons classified stage 2 or higher by cystatin C but not by CKD-EPI at the same time. Here, CST3 is linked to chronic kidney disease.